MDM2 and in situ carcinoma: Additionally, MDM2 amplifications were detected in a similar limited fraction of CIS [11] and the here analyzed pTa HG/papillary pT1 HG samples (~ 10–15%), justifying testing of MDM2 inhibitors in clinical trials.